Decreased level of serum NT-proCNP associates with disease severity in COVID-19

Respiratory Research

Table 1 Baseline characteristics, cardiovascular risk profile, comorbidities and relevant medications of the non-COVID-19 and COVID-19 groups of the study cohort

Characteristics	Non-COVID-19 (n = 35)	COVID-19 (n = 32)	p value
Baseline characteristics
Age years (SD)	61.7 (22.27)	59.9 (14.9)	0.71
Female n (%)	18 (51)	16 (50)	1.0
BMI kg/m² (IQR)	23.9 (4.49)	26.7 (6.5)	0.07
Previous medical history
Hypertension n (%)	18 (51)	12 (38)	0.3
Diabetes mellitus n (%)	6 (17)	7 (21.9)	0.76
Chronic kidney disease n (%)	4 (11)	4 (12.5)	1.0
Coronary artery disease n (%)	1 (3)	2 (6.3)	0.6
Heart failure n (%)	3 (9)	2 (6.3)	1.0
Cancer n (%)	13 (37)	10 (31.3)	0.78
Smoker n (%)	19 (54)	14 (43.8)	0.47
Pulmonary pathology n (%)	5 (14)	9 (28)	0.23
Relevant cardiovascular medications
ACEI n (%)	6 (17)	2 (6.3)	0.26
ARB n (%)	7 (20)	8 (25)	0.77
CCB n (%)	6 (17)	7 (21.9)	0.76

Continuous variables were described using mean and standard deviation (SD) for symmetric, and median and interquartile range (IQR) for asymmetric distributions. p values are from two-sample t tests (SD), Wilcoxon’s rank-sum test (IQR) or Fisher’s exact test (categorical variables). Pulmonary pathology is defined as COPD, prior pulmonary embolism or pulmonary fibrosis in the anamnesis
ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, BMI body mass index, CCB Ca²⁺ channel blocker, COPD chronic obstructive pulmonary disease, COVID-19 coronavirus disease 2019, IQR interquartile range, SD standard deviation

ISSN: 1465-993X